Specialty drug growth is accelerating, but billing infrastructure has not kept pace. High-cost therapies now represent a growing share of total drug spend and pipeline volume. At the same time, medical benefit claims, prior authorizations, payer policy changes and 340B…
Presented by:
Presenters
David Pope, PharmD
Chief Pharmacy Officer XiFin, Inc.
Mike Fauver
Vice President, Enterprise Solutions XiFin, Inc.
Heather Agostinelli
Vice President, Head of Specialty RCM XiFin, Inc.
